Diabetic-foot osteomyelitis
Diabetic-foot osteomyelitis (DFO) is a limb- and life-threatening complication of diabetic foot ulcers in which infection reaches bone; Staphylococcus aureus (including MRSA) is the single most common pathogen. Even with prolonged systemic antibiotics, DFO frequently fails to resolve because of poor vascular penetration to ischemic bone, dense biofilm, intracellular and small-colony-variant persistence, and rising antibiotic resistance, leaving amputation as a common fallback. Bacteriophages are well suited here because they self-amplify at the infection site, penetrate and degrade biofilm matrix, kill antibiotic-resistant and metabolically dormant S. aureus by mechanisms independent of antibiotics, and can be delivered topically into the wound and adjacent bone as an adjunct to standard care. This makes phage cocktails an attractive limb-salvage strategy precisely where antibiotics alone are insufficient.
How phages act here
Mechanism
Anti-staphylococcal phages bind specific surface receptors (e.g., wall teichoic acid) on S. aureus, inject their genome, hijack host machinery to replicate, and lyse the cell, releasing progeny that propagate the kill as long as susceptible bacteria remain. Because host range is strain-specific, programs match each patient's isolate to active phages via phage susceptibility testing and combine multiple phages into a cocktail to broaden coverage and suppress resistant mutants. Staphylococcal phages of the Kayvirus and Silviavirus genera (large, strictly lytic myoviruses) are favored for DFO because they encode depolymerases and lysins that disrupt biofilm extracellular polymeric substance, allowing penetration into the b-iofilm-shielded bacterial community on bone and necrotic tissue. Phage-antibiotic synergy is real but not universal — cocktails plus vancomycin can outperform either agent alone, whereas some combinations (e.g., with linezolid) show no added benefit, so pairing must be tested empirically. Engineered and CRISPR-armed phages that resensitize bacteria or carry sequence-specific killing payloads are an active preclinical direction but are not yet part of DFO clinical practice.
Where it stands
Current evidence
Evidence has advanced from compassionate-use case reports to a completed randomized controlled trial. The landmark study is BiomX's BX211 DANCE Phase 2b trial (NCT05177107; originally run by Adaptive Phage Therapeutics, whose assets BiomX acquired): a randomized, double-blind, placebo-controlled, multi-site study of personalized anti-S. aureus phage therapy plus standard of care in DFO. Topline results announced 31 March 2025 enrolled 41 patients (2:1 randomization; 26 BX211 via IV plus weekly topical dosing through week 12, 15 placebo), all receiving standard-of-care antibiotics. BX211 was safe and well tolerated and produced a statistically significant, sustained reduction in ulcer surface area (percent area reduction p=0.046 at week 12; p=0.052 at week 13), with separation from placebo from about week 7 and the strongest effect in patients whose ulcers extended to bone depth. BiomX reported it is planning a Phase 2/3 trial pending FDA feedback. Supporting clinical evidence includes a 2023 UK case series of 10 high-amputation-risk diabetic-foot-infection patients given adjunctive topical anti-staphylococcal phage (9/10 judged to benefit; limb salvage in 6/10) and a 2018 case report of conservatively treated digital S. aureus DFO resolved with phage. Additional registered/ongoing European trials in the diabetic-foot space include PhagoPied, REVERSE/REVERSE2.
Evidence confidence: medium
The data
Key studies & trials
- BiomX Inc. BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO). Press release, 31 March 2025. (DANCE Phase 2b; NCT05177107; 41 patients; PAR p=0.046 at week 12). ↗
- Phase 2b Randomized, Parallel, Double-blind, Placebo-Controlled, Repeat Dose, Multi-Site Study for Safety, Tolerability, and Efficacy of Personalized Phage Treatment and Standard of Care for Subjects With Diabetic Foot Osteomyelitis Due to S. aureus (DANCE). Sponsor: Adaptive Phage Therapeutics / BiomX. ClinicalTrials.gov identifier NCT05177107. ↗
- Plumet L, et al. Phage therapy: a promising approach for Staphylococcus aureus diabetic foot infections. Journal of Virology. 2025;99. doi:10.1128/jvi.00458-25 (PMC12172479). ↗
- Young MJ, Hall LML, Merabishvili M, Pirnay JP, Clark JR, Jones JD. Phage Therapy for Diabetic Foot Infection: A Case Series. Clinical Therapeutics. 2023;45(8):797-801. PMID 37442654. doi:10.1016/j.clinthera.2023.06.009 ↗
Who is working on it
Programs & centers
The possibility
If the Phase 2/3 program confirms the DANCE signal, personalized anti-S. aureus phage cocktails could become a standard adjunct that turns many bone-deep diabetic foot infections from amputation candidates into limb-salvage successes, treating the patient's own resistant strain rather than guessing with broad antibiotics. As rapid phage-susceptibility matching and biobanked Kayvirus/Silviavirus libraries mature, a clinician could one day swab an ulcer, identify the offending S. aureus within days, and apply a tailored, self-amplifying, biofilm-dissolving cocktail directly into the wound. Engineered and lysin-based phages may extend this even to the dormant, intracellular bacteria that antibiotics never reach, reshaping how the world's roughly half-billion people with diabetes keep their feet.